LYC-55716 (CINTIRORGON)
$180.00 – $1,200.00
Cintirorgon (CAS No.: 2055536-64-4), is a first-in-class, selective and orally bioavailable RORγ agonist. Cintirorgon (LYC-55716) modulates gene expression of RORγ expressing T lymphocyte immune cells, resulting in enhanced effector function, as well as decreased immunosuppression, resulting in decreased tumor growth, and improved survival. >99.5% Purity.
Synonyms: LYC-55716, LYC55716, RORγ agonist
For Research Use Only.
- Details & Specifications
- References
- More Offers
| Catalog No. | APIM050044 |
|---|---|
| Product Name | LYC-55716 (CINTIRORGON) |
Description
APIM050044: Cintirorgon (LYC-55716) is a first-in-class, selective and orally bioavailable RORγ agonist. Cintirorgon (LYC-55716) modulates gene expression of RORγ expressing T lymphocyte immune cells, resulting in enhanced effector function, as well as decreased immunosuppression, resulting in decreased tumor growth, and improved survival.
CAS No.: 2055536-64-4
IUPAC/Chemical Name: (S)-3-(6-(3-(difluoromethoxy)-5-fluorophenyl)-4-((3-(trifluoromethyl)phenyl)sulfonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)-2,2-dimethylpropanoic acid
Molecular Formula: C27H23F6NO6S
Molecular Weight: 603.53
Purity: >99.5% chemical and optical purity (by achiral and chiral HPLCs)
QC: Achiral and Chiral HPLCs, MS, NMR, and Quantitative Elemental Analysis Report
Solubility: Soluble in DMSO
Storage: Dry, dark and at 0 – 4 C for short term (days to weeks) or -20 C for long term (months to years).
Note: Please contact us for COA, Spectra, and SDS information.
Background Information:
Target: RORγ
In Vivo: Upon oral administration of RORγ agonist Cintirorgon (LYC-55716) (CAS No. 2055536-64-4), this agent selectively binds to the nuclear receptor transcription factor RORγ, forming a receptor complex that translocates to the nucleus, and binds to ROR response elements (ROREs), enhancing the function, proliferation and survival of type 17 T cells, including Th17 (helper T cells) and Tc17 (cytotoxic T cells). RORγ, the nuclear receptor transcription factor that is involved in Th17/Tc17 differentiation, plays a key role in immune activation. Cintirorgon (LYC-55716) is also orally bioavailable, while the new generation of immuno-oncology drugs-ncluding PD-1/PD-L1 inhibitors are delivered by injection. [1]
What is the solubility of Cintirorgon (LYC-55716) (CAS No. 2055536-64-4) in vitro?
DMSO: > 113.3 mg/mL
What is the solubility of Cintirorgon (LYC-55716) (CAS No. 2055536-64-4) in vivo?
DMSO, PEG300, Tween-80, and saline
Please add 10% DMSO, 40% PEG300, 5% Tween-80, and 45% saline in order, solubility: 2.5 mg/mL.
Reference:
[1]. Aicher, T. D. et al. “Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ) Agonist for Use in Treating Cancer”, J. Med. Chem., 2021, 64, 13410-13428.
[2]. Weems, G. A. et al. “Lyc-55716: A novel small-molecule RORγ agonist immuno-oncology agent: Rationale for tumor selection and clinical evaluation of gastric and esophageal carcinoma in phase 2a expansion.”, J. Clin. Oncol., 2018, DOI: 10.1200/JCO.2018.36.4_suppl.67
[3]. Park, S. A. et al. “TIMP-1 mediates TGF-β-dependent crosstalk between hepatic stellate and cancer cells via FAK signaling”, Sci. Rep., 2015, 5, 16492.
[4]. Han, K. et al. “EW-7197 eluting nano-fiber covered self-expandable metallic stent to prevent granulation tissue formation in a canine urethral model”, Plos One 2018, https://doi.org/10.1371/journal.pone.0192430.
[5]. Yoon, S.-H. et al. “EW-7197, a Transforming Growth Factor-Beta Type I Receptor Kinase Inhibitor, Ameliorates Acquired Lymphedema in a Mouse Tail Model”, Lymphat. Res. Biol., 2020, https://doi.org/10.1089/lrb.2018.0070
[6]. Kim, B.-G. et al. “Abstract 2647: TGF-β type I receptor inhibitor (TEW-7197) diminishes myeloma progression by multiple immunomodulatory mechanisms in combination with ixazomib”, Cancer Res., 2017, DOI: 10.1158/1538-7445.AM2017-2647.
[7]. Malek, E. et al. “Preclinical Studies and a Phase I Trial of the TGF-β Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Refractory to Bortezomib or Lenalidomide”, Blood, 2018, https://doi.org/10.1182/blood-2018-99-112449
[8]. Song, K.-M. et al. “AB083. TEW-7197, a novel orally bioavailable activin receptor-like kinase 5 inhibitor, promotes regression of fibrotic plaque in a rat model of Peyronie’s disease”, Transl. Androl. Urol., 2018, doi: 10.21037/tau.2018.AB083
[9]. Kim, B.-G. et al. “Vactosertib, a TGF-ß Receptor I Kinase/ALK5 Inhibitor, Diminishes Tumor Progression and Bone Disease in a Mouse Model of Multiple Myeloma and Overcomes Resistance to Proteasome Inhibitors”, Blood, 2018, https://doi.org/10.1182/blood-2018-99-117852
[10]. Jin, C. H. et al. “Discovery of N-((4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of TGF-β Type I Receptor Kinase as Cancer Immunotherapeutic/Antifibrotic Agent”, J. Med. Chem., 2014, https://doi.org/10.1021/jm500115w
Frequent questions related to “Cintirorgon (LYC-55716) (CAS No. 2055536-64-4), a first-in-class, selective and orally bioavailable RORγ agonist”:
Who makes Cintirorgon?
What is Cintirorgon?
What is the mechanism of action for Cintirorgon?
Popular searches related to “Cintirorgon (LYC-55716) (CAS No. 2055536-64-4), a first-in-class, selective and orally bioavailable RORγ agonist”:
Cintirorgon results
Cintirorgon fda approval
Cintirorgon mechanism of action
Cintirorgon price
Cintirorgon synthesis
Cintirorgon analogue
Cintirorgon structure activity study
Cintirorgon in vitro
Cintirorgon in vivo
Cintirorgon supplier
Cintirorgon clinical study
Cintirorgon Cytotoxicity
Cintirorgon Target
Cintirorgon RORγ agonist
RORγ agonist
Cintirorgon purchase
